The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.

Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 pushes well beyond what Wall Street consensus currently projects, and the catalysts behind each target may surprise you.

Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.

Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.

By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.

Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

They have businesses built to handle the toughest environments.

The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec

The biosimilar drag on Johnson & Johnson stock is shrinking, and the business underneath it is already growing at a double-digit pace.

AbbVie has another blockbuster business emerging.

AbbVie stock has delivered a strong 152.2% return over the past 5 years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market based multiples look less comfortable. At around US$249.46 per share, investors are weighing a rich recent track record against checks that suggest the shares are not a straightforward bargain. Over the past 5 years AbbVie has returned 152.2%, which puts more pressure on today’s buyers to judge...

AbbVie has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per share while the index has gained 13.5%.

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.